Compare Novartis AG (NVS) vs Johnson & Johnson (JNJ) Stock

Novartis AG (NVS) offers the better valuation at 23.5x trailing P/E (19.0x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novartis AG (NVS) is the cheapest at 23.5x versus Johnson & Johnson at 42.9x. On forward P/E, Novartis AG is actually cheaper at 19.0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novartis AG wins at 1.24x versus Johnson & Johnson's 38.22x — a reasonable growth-adjusted valuation.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +119.5%, compared to +70.8% for Johnson & Johnson (JNJ). A $10,000 investment in NVS five years ago would be worth approximately $22K today (assuming dividends reinvested). Over 10 years, the gap is even starker: NVS returned +221.6% versus JNJ's +175.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.06β versus Novartis AG's 0.24β — meaning NVS is approximately 335% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Johnson & Johnson (JNJ) carries a lower debt/equity ratio of 51% versus 80% for Novartis AG — giving it more financial flexibility in a downturn.

Novartis AG (NVS) is the more profitable company, earning 25.6% net margin versus 15.8% for Johnson & Johnson — meaning it keeps 25.6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31.2% versus 24.9% for JNJ. At the gross margin level — before operating expenses — NVS leads at 75.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Novartis AG (NVS) is the more undervalued stock at a PEG of 1.24x versus Johnson & Johnson's 38.22x. A PEG below 1.5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Novartis AG (NVS) trades at 19.0x forward P/E versus 21.5x for Johnson & Johnson — 2.5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JNJ: -7.7% to $229.33.

All stocks in this comparison pay dividends. Novartis AG (NVS) offers the highest yield at 2.4%, versus 2.0% for Johnson & Johnson (JNJ).

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.06), 2.0% yield, +175.7% 10Y return). Both have compounded well over 10 years (JNJ: +175.7%, NVS: +221.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.